Sanofi has completed the acquisition of messenger RNA (mRNA) therapies firm Translate Bio to expedite the use mRNA technology for the development of treatments and vaccines. The latest move
US-based biopharmaceutical firm AzurRx BioPharma has agreed to acquire clinical-stage biotechnology company First Wave Bio in a stock-and-cash deal valued at $229m. First Wave Bio is focussing on
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Amgen’s sotorasib (Lumakras) to treat patients with specific non-small cell lung cancer with KRAS G12C mutation. To be
A first-in class antibody, lenzilumab binds to and neutralises granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is a key cytokine that causes a hyperinflammatory cascade or cytokine storm associated to
The Phase 2, two-arm, randomised, double blind, placebo controlled, multicentre study will evaluate the efficacy and safety of Ampligen in 80 subjects suffering with PCCD. This trial will
EnGeneIC has started dosing in Phase I clinical trial of the world’s first nanocellular technology-based anti-Covid-19 vaccine in healthy adults. Referred to as EnGeneIC Dream Vector (EDV), the
Adaptimmune Therapeutics has signed a strategic partnership and licence agreement with Roche Group member, Genentech, for the development and commercialisation of allogeneic cell therapies across several cancer indications.
The European Medicines Agency (EMA) has started evaluation of the data on a booster (third) dose for the Covid-19 vaccine, Comirnaty, developed by Pfizer and BioNTech. The move
This trial will evaluate the safety, tolerability and immunogenicity of Reliance’s vaccine against Covid-19 infection in healthy subjects. The trial will also analyse the maximum tolerated dose of
The US Food and Drug Administration (FDA) has granted fast track designation for Novartis’ agonist LNA043 to treat knee osteoarthritis. LNA043, which has been discovered within the Novartis
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.